EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epitope-directed selection of GPCR nanobody ligands with evolvable function

Meredith A Skiba iD, Clare Canavan iD, Genevieve R Nemeth, Jinghan Liu, Ali Kanso iD, Andrew C Kruse iD

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2423931122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Meredith A Skiba und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Epitopes, Receptor, Angiotensin, Type 1, Receptors, G-Protein-Coupled. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | NIH (NIH), NICHD NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibodies have the potential to target G protein–coupled receptors (GPCRs) with high receptor, cellular, and tissue selectivity; however, few antibody ligands for GPCRs exist. Here, we describe a generalizable selection method to enrich for GPCR ligands from a synthetic camelid antibody fragment (nanobody) library. Our strategy yielded multiple nanobody ligands for the angiotensin II type I receptor (AT1R), a prototypical GPCR and important drug target. We found that nanobodies readily act as allosteric modulators, encoding selectivity for both the receptor and chemical features of GPCR ligands. We then used structure-guided design to convert two nanobodies from allosteric ligands to competitive AT1R inhibitors through simple mutations. This work demonstrates that nanobodies can encode multiple pharmacological behaviors and have great potential as evolvable scaffolds for the development of next-generation GPCR therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesEpitopesReceptor, Angiotensin, Type 1Receptors, G-Protein-CoupledLigandsHumansHEK293 CellsAnimalsAllosteric Regulation

Stichwörter der Autor:innen

GPCRallosteryangiotensincryo-EMnanobody

Substanzen

Single-Domain AntibodiesLigandsEpitopesReceptor, Angiotensin, Type 1Receptors, G-Protein-Coupled

Autor:innen und Institutionen

  • Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115.

ORCID-Profile: Meredith A Skiba, Clare Canavan, Ali Kanso, Andrew C Kruse

Förderung

  • HHS | NIH (NIH)
  • NICHD NIH HHS
  • NCI NIH HHS

Zitieren

APA

Skiba, M. A., Canavan, C., Nemeth, G. R., Liu, J., Kanso, A., & Kruse, A. C. (2025). Epitope-directed selection of GPCR nanobody ligands with evolvable function. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2423931122

Vancouver

Skiba MA, Canavan C, Nemeth GR, Liu J, Kanso A, Kruse AC. Epitope-directed selection of GPCR nanobody ligands with evolvable function. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2423931122

BibTeX
@article{Skiba2025,
  author = {Skiba, Meredith A and Canavan, Clare and Nemeth, Genevieve R and Liu, Jinghan and Kanso, Ali and Kruse, Andrew C},
  title = {Epitope-directed selection of GPCR nanobody ligands with evolvable function},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2423931122}
}
Kostenlos starten →